Steatohepatitis
Disease5 papers3 findings
- Humans2
Interventions
1GLP-1 receptor agonists
downin humans1
1 study
GLP-1 receptor agonists
downin humans1
GLP-1 receptor agonists decrease steatohepatitis in humans.
Reviewinjectable
The Evolution of Medications for Obesity Management · JGH open : an open access journal of gastroenterology and hepatology · 4 Sep 2026
Upstream
1Met-TL
mediatesin humans1
1 study
Met-TL
mediatesin humans1
Met-TL mediates steatohepatitis in humans (8.2%).
Humansn = 5,957
Metabolomic profiling of telomere length: associations with aging-related phenotypes and modifiable lifestyle factors in Chinese older adults · The journals of gerontology. Series A, Biological sciences and medical sciences · 28 Aug 2026
Associations
1Met-TL
upin humans1
1 study
Met-TL
upin humans1
Met-TL is associated with steatohepatitis in humans.
Humansn = 5,957
Metabolomic profiling of telomere length: associations with aging-related phenotypes and modifiable lifestyle factors in Chinese older adults · The journals of gerontology. Series A, Biological sciences and medical sciences · 28 Aug 2026
Trial sponsors
Aristotle University Of Thessaloniki
1 trialPhase 230 people
Austrian Breast & Colorectal Cancer Study Group
1 trialPhase 28 people
Funding
National Institute of Diabetes and Digestive and Kidney DiseasesUS$250k1 grant since 2002
Latest
29Three-protein combination eased chronic liver disease in rats
In experiments in male Wistar rats, intermittently producing three gene-regulating proteins reduced chronic liver injury and scarring and increased…In experiments in male Wistar rats, intermittently producing three gene-regulating proteins reduced chronic liver injury and scarring and increased survival.
Dasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence…The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
AGA Clinical Practice Update on Surveillance of Pancreatic Cystic Lesions and Hepatocellular Carcinoma in Older Adults: Expert Review
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
Dapagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential
Nutrient deficits linked to higher metabolic risks in obesity
Compared to patients without nutritional deficiencies, vitamin D and B12 deficits carried median hazard ratios of 3.09 and 2.49 for metabolic diseases…Compared to patients without nutritional deficiencies, vitamin D and B12 deficits carried median hazard ratios of 3.09 and 2.49 for metabolic diseases in obesity.